Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07419490 · ClinicalTrials.gov registry record · NA

Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy

A NA study of Colorectal (Colon or Rectal) Cancer and Pelvic Malignancies, sponsored by University of South Florida.

Recruiting
Registry status
NA
Development phase
26
Enrollment target
1
Study location

NCT07419490: Recruiting NA study of Colorectal (Colon or Rectal) Cancer and Pelvic Malignancies, sponsored by University of South Florida.

NCT07419490 is a NA study of Colorectal (Colon or Rectal) Cancer and Pelvic Malignancies that is actively recruiting participants, run by University of South Florida. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07419490, a NA study of Colorectal (Colon or Rectal) Cancer and Pelvic Malignancies, is actively recruiting participants, sponsored by University of South Florida.

RECRUITING
Registry status
NA
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This study is designed as a Phase I clinical trial enrolling female patients aged 18-40 years who have been diagnosed with pelvic malignancies requiring whole pelvic external radiation therapy (WPXRT) and who express interest in preserving fertility and ovarian function. The trial's primary objective is to assess the feasibility and safety of uterine and ovarian transposition (UOT). Premenopausal women under the age of 40 will undergo UOT using a novel minimally invasive approach. Feasibility and safety will be evaluated through standardized postoperative assessments, including: (A) success in mobilizing and repositioning the uterus, ovaries, and fallopian tubes while maintaining vascular integrity; (B) documentation of surgical complications; (C) monitoring the timeliness and adherence to planned WPXRT. To enhance safety and optimize outcomes, intraoperative imaging with indocyanine green fluorescence and Doppler ultrasonography will be employed. Short-term success will be defined by technical success in repositioning the uterus and ovaries with preserved vascular integrity, absence of major surgical complications, and timely initiation and completion of WPXRT. Long-term success will be evaluated by the preservation of fertility. The study's primary objective is also to evaluate surgical, reproductive, and quality-of-life outcomes following UOT. This objective will determine the procedure's efficacy in preserving ovarian and menstrual function and its potential to support future pregnancies. Endpoints include: (A) maintenance of normal premenopausal levels of FSH, LH, AMH, and estradiol at defined postoperative intervals; (B) assessment of menstrual timing, regularity, and characteristics to document return of ovulatory cycles; (C) evaluation of uterine integrity and reproductive potential using pelvic ultrasonography; (D) comprehensive evaluation of patient quality of life encompassing physical, emotional, sexual, and reproductive well-being. These measu

Primary Outcome

Success of uterine transposition (feasibility) will be defined as the percentage of cases in which the uterus, ovaries, and fallopian tubes are successfully mobilized and repositioned as planned without the need for intraoperative conversion. Unit of Measure: Percentage of participants (%) Time Frame: up 30 days postsurgery.

Interventions

  • PROCEDURE Uteroovarian transposition

Study Locations (1)

Florida

  • Tampa General Hospital - Tampa

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2026-03-20
Est. Completion 2031-06
Phase NA
University of South Florida

252 total trials

What NCT07419490 shows while recruiting

NCT07419490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Colorectal (Colon or Rectal) Cancer appearing as the primary indexed condition, and to 1 intervention - of which Uteroovarian transposition is the first listed.

NCT07419490 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07419490 about?

NCT07419490 is a clinical study titled "Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy". This study is designed as a Phase I clinical trial enrolling female patients aged 18-40 years who have been diagnosed with pelvic malignancies requiring whole pelvic external radiation therapy (WPXRT) and who express interest in preserving fertility and ovarian function. The trial's primary objecti...

What is the current status of trial NCT07419490?

This trial is currently recruiting. It is a NA study. The enrollment target is 26 participants. The study started on 2026-03-20. Estimated completion is 2031-06.

What conditions does trial NCT07419490 study?

This clinical trial studies the following conditions: Colorectal (Colon or Rectal) Cancer, Pelvic Malignancies, Oncofertility.

What interventions are being tested in trial NCT07419490?

The interventions under investigation include: Uteroovarian transposition (PROCEDURE).

Who is sponsoring clinical trial NCT07419490?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07419490 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal (Colon or Rectal) Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07419490's enrollment target sits among peer trials

26 1710th of 2000 higher than 289 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07419490, the US trial registry maintained by the National Library of Medicine. NCT07419490 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.